Scaling up and scaling out: expanding patient access with in vivo CAR-T

“If in vivo technology can turn CAR‑T from a high-resource, intensive therapy into a broadly accessible treatment modality, the field will have delivered on its promise.”

Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights , speaks with Grant Boldt, Chief Operating Officer, CPTx, about the development of non-viral, DNA-based in vivo CAR‑T cell therapies, the trade-offs between viral, RNA, and DNA delivery approaches, and how in vivo strategies could make CAR‑T more scalable, accessible, and affordable.

Please enter your email to access content Read now